Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
VIPER-101 by ViTToria Biotherapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
VIPER-101 is under clinical development by ViTToria Biotherapeutics and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...
Data Insights
VIPER-101 by ViTToria Biotherapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
VIPER-101 is under clinical development by ViTToria Biotherapeutics and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...